Category: Metabolic & Body Composition

What Incretin Trials Measure Beyond Weight Loss

Posted on July 29, 2026

Introduction

A changing body in midlife can make the scale feel louder than it deserves to be. Weight may rise around the waist, muscle can feel harder to keep, and the old rules about food, sleep, and activity may stop behaving predictably. The better question is not simply whether weight changes. It is what changes inside that number.

That is where incretin trials become useful. These are human studies of drugs that act on hormone pathways involved in appetite and blood sugar. Tirzepatide has the largest published evidence base here; retatrutide is earlier. The trials can tell us a lot about body weight, waist size, blood sugar, and maintenance. They cannot yet tell us enough about menopause, muscle function, or what happens across decades.

Research Confidence

★★★★☆ Four of five. Tirzepatide has several large randomized trials, meaning people were assigned by chance to tirzepatide or placebo for a fairer comparison. The rating is not five because most trials were industry-funded, under two years, and did not report menopausal status or sex-specific outcomes in enough detail.

Study Snapshot

• Study type: randomized, double-blind, placebo-controlled phase 3 trial
• Participants: 2,539 adults with obesity or overweight, mean age 44.9 years, 67.5% women
• Duration: 72 weeks
• Measured: percent change in body weight from the start of the trial
• Found: mean weight change was -15.0%, -19.5%, and -20.9% with tirzepatide 5, 10, and 15 mg, compared with -3.1% with placebo
• Funding: Eli Lilly funded the trial

Why This Matters

Midlife weight change is rarely just a math problem. Sleep can shorten, hot flashes can disrupt recovery, injuries can interrupt training, and insulin sensitivity often worsens with age. Waist size may change even when total body weight does not move much.

For someone reading an incretin trial, that means the headline number is only the doorway. A 15% or 20% average weight change tells you the trial moved body mass. It does not tell you whether strength improved, whether lean tissue was preserved, whether the result lasted after the study drug stopped, or whether women in perimenopause responded differently from younger women.

The useful reading starts when the scale stops being the whole story.

Why Incretin Trials Start With The Scale

In the SURMOUNT-1 human randomized trial, 2,539 adults without diabetes were assigned to tirzepatide or placebo for 72 weeks. Double-blind means neither participants nor trial staff knew who received which assignment during the study. The primary endpoint, the main result the trial was built to test, was percent body-weight change.

That endpoint was met clearly. Average weight change ranged from -15.0% to -20.9% across tirzepatide groups, compared with -3.1% with placebo. SURMOUNT-2, in 938 adults with type 2 diabetes, also reported greater weight reduction with tirzepatide than placebo, though the average changes were smaller than in adults without diabetes.

Those numbers matter because body weight is measurable, familiar, and clinically relevant. But a scale is blunt. It cannot say whether a smaller body is metabolically healthier, functionally stronger, or easier to live in.

What The Better Incretin Trials Measure Next

The stronger incretin trials added measures that give the scale some context. SURMOUNT-1 tracked waist circumference, blood pressure, insulin, lipids, and participant-reported physical function. In plain English, researchers were asking whether weight change came with changes around the abdomen, the heart-metabolic system, and daily movement.

SURMOUNT-3 asked a different question. After a 12-week intensive lifestyle lead-in, 806 adults were assigned to tirzepatide or placebo for 72 weeks. That design tested whether a medication period added further weight change after structured lifestyle work. SURMOUNT-4 then tested maintenance. After all participants received open-label tirzepatide for 36 weeks, meaning everyone knew they were receiving it, 670 adults were randomized either to continue tirzepatide or switch to placebo for 52 more weeks. Those who switched regained weight on average.

That maintenance trial is especially relevant in midlife. The question is not only whether weight can change during a controlled study. It is whether the body defends the old weight when the intervention changes.

Where Tirzepatide And Retatrutide Sit In This Literature

Tirzepatide acts on two incretin-related receptors, GIP and GLP-1. In Canada and the United States, tirzepatide is approved as a branded prescription drug for specific medical indications. Research-use tirzepatide supplied for laboratory investigation is not an approved medicine and should not be treated as interchangeable with a prescribed product.

Retatrutide is further back in the evidence chain. In a phase 2 human randomized trial of 338 adults with obesity, retatrutide, which acts on GIP, GLP-1, and glucagon receptors, produced larger average weight changes than placebo over 48 weeks. Phase 2 means the study was still relatively early: useful for signal, dosing exploration, and safety monitoring, but not the final word.

The important distinction is maturity. Tirzepatide has phase 3 trial data across several populations. Retatrutide remains investigational, with larger confirmatory trials needed.

What This Means For You

When you read about incretin trials, look for the endpoints before the headline. Ask what was measured: body weight, waist size, blood sugar, blood pressure, quality of life, adverse events, discontinuation, or weight regain after stopping.

Also ask what was not measured. A trial can show average weight change without proving better strength, better long-term function, or a menopause-specific result. If you are discussing this research with a clinician, the practical questions are usually about eligibility, risks, monitoring, lean-mass preservation, and what happens when the intervention ends. The literature does not support turning a trial regimen into a personal plan.

What This Tells Us About Women Specifically

Women were well represented numerically in several tirzepatide trials. SURMOUNT-1 enrolled 67.5% women, and SURMOUNT-4 enrolled about 70% women. That is better than many metabolic studies.

The problem is what the papers did not report. Menopausal status was not a central reported variable, hormone therapy use was not clearly accounted for in the main publications, and results were not presented in a way that answers whether perimenopausal or postmenopausal women responded differently. For a midlife reader, that gap matters. Female enrollment is not the same thing as women-specific evidence.

Questions This Study Couldn't Answer

• The major tirzepatide trials were not designed around menopause, perimenopause, or hormone therapy use.
• Most follow-up was measured in months, not decades.
• Weight and waist change were reported more clearly than strength, physical performance, or day-to-day function.
• Gastrointestinal adverse events were common in the tirzepatide trials, and discontinuation varied by study and dose.
• The trials were funded by Eli Lilly, the manufacturer, so independent long-term replication remains important.

Future Research

The confidence rating would rise with longer independent trials that track body composition, strength, bone, weight maintenance, and adverse events after discontinuation. For women in midlife, the missing study is obvious: stratify by menopausal status, record hormone therapy, and report results separately enough to be useful.

Sources

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022. Human RCT, n=2,539. https://doi.org/10.1056/NEJMoa2206038
2. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. Human RCT, n=670 randomized after lead-in. https://doi.org/10.1001/jama.2023.24945
3. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after Intensive Lifestyle Intervention in Adults with Overweight or Obesity: The SURMOUNT-3 Phase 3 Trial. Nature Medicine. 2023. Human RCT, n=806. https://doi.org/10.1038/s41591-023-02597-w
4. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes: SURMOUNT-2. The Lancet. 2023. Human RCT, n=938. https://doi.org/10.1016/S0140-6736(23)01200-X
5. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023. Human RCT, n=338. https://doi.org/10.1056/NEJMoa2301972

Research Use And Availability

Nu-Forme Labs supplies tirzepatide as a research-use-only material in Canada for laboratory investigation, with documentation and third-party testing standards. The relevant internal pages are the tirzepatide product category page, metabolic research category, peptide glossary, and research-use-only standards page. This article discusses clinical trial literature, not personal use or prescribing.

Final Thoughts

Incretin trials are more informative when read as measurement studies, not just weight-loss stories. Tirzepatide has strong human evidence for trial endpoints such as body weight and maintenance under study conditions. The harder midlife questions, especially around muscle, menopause, and long-term function, are still waiting for better-designed answers.